A 52-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Ustekinumab in Patients With Moderate-to-Severe Plaque Psoriasis

Trial Profile

A 52-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Ustekinumab in Patients With Moderate-to-Severe Plaque Psoriasis

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Jun 2017

At a glance

  • Drugs Ixekizumab (Primary) ; Ustekinumab
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms IXORA-S
  • Sponsors Eli Lilly
  • Most Recent Events

    • 02 Jun 2017 This trial has been completed in Austria (End date:2017-05-15) as per European Clinical Trials Database record.
    • 24 May 2017 This trial has been completed in Hungary (End date:2017-05-15) as per European Clinical Trials Database record.
    • 19 May 2017 Primary endpoint (Proportion of Participants with a 90% Improvement in Psoriasis Area and Severity Index (PASI 90) from Baseline) has been met,as per results published in the British Journal of Dermatology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top